DK1200073T3 - Selektive iGluR5-receptorantagonister til behandling af migræne - Google Patents

Selektive iGluR5-receptorantagonister til behandling af migræne

Info

Publication number: DK1200073T3
Authority: DK; Denmark
Prior art keywords: migraine; treatment; receptor antagonists; iglur5 receptor; selective iglur5
Prior art date: 1999-07-06

Application number

DK00944671T

Other languages

Danish (da)

English (en)

Inventor

David Bleakman

Paul Leslie Ornstein

Amy Suzon Chappell

Sandra Ann Filla

Kirk Willis Johnson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-06

Filing date

2000-06-27

Publication date

2007-05-07

2000-06-27 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2007-05-07 Application granted granted Critical

2007-05-07 Publication of DK1200073T3 publication Critical patent/DK1200073T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Addiction (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK00944671T 1999-07-06 2000-06-27 Selektive iGluR5-receptorantagonister til behandling af migræne DK1200073T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US14248599P	1999-07-06	1999-07-06
US15116599P	1999-08-27	1999-08-27
PCT/US2000/016297 WO2001001972A2 (en)	1999-07-06	2000-06-27	SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Publications (1)

Publication Number	Publication Date
DK1200073T3 true DK1200073T3 (da)	2007-05-07

Family

ID=26840135

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00944671T DK1200073T3 (da)	1999-07-06	2000-06-27	Selektive iGluR5-receptorantagonister til behandling af migræne

Country Status (28)

Country	Link
US (4)	US6566370B1 (tr)
EP (1)	EP1200073B1 (tr)
JP (1)	JP4619595B2 (tr)
KR (1)	KR20020024300A (tr)
CN (1)	CN1230174C (tr)
AR (1)	AR029373A1 (tr)
AU (1)	AU773304B2 (tr)
BR (1)	BR0012175A (tr)
CA (1)	CA2378613C (tr)
CZ (1)	CZ20014488A3 (tr)
DE (1)	DE60032905T2 (tr)
DK (1)	DK1200073T3 (tr)
DZ (1)	DZ3209A1 (tr)
EA (1)	EA004290B1 (tr)
ES (1)	ES2278619T3 (tr)
HK (1)	HK1047036A1 (tr)
HR (1)	HRP20020013A2 (tr)
HU (1)	HUP0202253A3 (tr)
IL (1)	IL146697A0 (tr)
MX (1)	MXPA01012726A (tr)
MY (1)	MY133503A (tr)
NO (1)	NO20016246L (tr)
NZ (1)	NZ515616A (tr)
PE (1)	PE20010299A1 (tr)
PT (1)	PT1200073E (tr)
SK (1)	SK112002A3 (tr)
TR (1)	TR200200066T2 (tr)
WO (1)	WO2001001972A2 (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6579886B2 (en)	1999-12-22	2003-06-17	Eli Lilly And Company	Selective iglur5 receptor antagonists
EP1351952A2 (en) *	2001-01-05	2003-10-15	Eli Lilly And Company	Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
CN100548299C (zh) *	2001-01-05	2009-10-14	伊莱利利公司	兴奋性氨基酸受体拮抗剂
US6924294B2 (en)	2001-01-05	2005-08-02	Eli Lilly And Company	Excitatory amino acid receptor antagonists
US7205313B2 (en)	2001-01-05	2007-04-17	Eli Lilly And Company	Excitatory amino acid receptor antagonists
EP1351951A2 (en) *	2001-01-05	2003-10-15	Eli Lilly And Company	Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
AU2002241565A1 (en) *	2001-01-05	2002-07-16	Eli Lilly And Company	Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
DZ3460A1 (fr) *	2001-01-05	2002-07-11	Lilly Co Eli	Antagonistes du recepteur d'acide amine excitateur
GB0128996D0 (en)	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
US20040082606A1 (en) *	2001-12-20	2004-04-29	Khau Vien Van	Excitatory amino acid receptor antagonists
MXPA04009857A (es)	2002-04-26	2004-12-07	Lilly Co Eli	Derivados de ester con un acido decahidroisoquinoli-3-carboxilico como analgesicos.
US7960436B2 (en)	2006-06-05	2011-06-14	Valeant Pharmaceuticals International	Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en)	2006-08-23	2015-03-31	Valeant Pharmaceuticals International	N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
NZ575652A (en)	2006-08-23	2011-08-26	Valeant Pharmaceuticals Int	Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en)	2006-10-10	2014-05-13	Valeant Pharmaceuticals International	N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt)	2006-11-28	2014-01-21	Valeant Pharmaceuticals Int	Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en)	2007-06-13	2013-02-05	Valeant Pharmaceuticals International	Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en)	2007-08-01	2013-10-22	Valeant Pharmaceuticals International	Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en)	2007-08-13	2010-08-31	Valeant Pharmaceuticals International	Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
AU2018310881C1 (en)	2017-07-31	2021-12-16	Novartis Ag	Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
JOP20200216A1 (ar)	2018-03-05	2020-09-03	Janssen Pharmaceutica Nv	تجارب للكشف عن التنكس العصبي
TWI886158B (zh)	2019-10-10	2025-06-11	加拿大商再諾製藥公司	選擇性鉀通道調節劑之固態晶型
JP2022553569A (ja)	2019-11-08	2022-12-23	ゼノン・ファーマシューティカルズ・インコーポレイテッド	うつ病性障害の治療方法
WO2022173855A1 (en)	2021-02-09	2022-08-18	Xenon Pharmaceuticals Inc.	Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5284957A (en)	1992-09-03	1994-02-08	Eli Lilly And Company	Excitatory amino acid receptor antagonists
US5356902A (en) *	1992-11-06	1994-10-18	Eli Lilly And Company	Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en)	1994-05-31	1995-08-29	Eli Lilly And Company	Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) *	1994-11-18	1998-06-16	The General Hospital Corporation	Method for treating vascular headaches
ID23013A (id) *	1997-04-07	1999-12-30	Lilly Co Eli	Bahan-bahan farmakologi
DE60002733T2 (de)	1999-07-06	2004-03-18	Eli Lilly And Co., Indianapolis	Diester prodrugs von decahydroischinoline-3-carbonsäure

2000
- 2000-06-27 KR KR1020027000138A patent/KR20020024300A/ko not_active Withdrawn
- 2000-06-27 JP JP2001507466A patent/JP4619595B2/ja not_active Expired - Fee Related
- 2000-06-27 HK HK02107174.1A patent/HK1047036A1/zh unknown
- 2000-06-27 EP EP00944671A patent/EP1200073B1/en not_active Expired - Lifetime
- 2000-06-27 IL IL14669700A patent/IL146697A0/xx unknown
- 2000-06-27 DZ DZ003209A patent/DZ3209A1/xx active
- 2000-06-27 PT PT00944671T patent/PT1200073E/pt unknown
- 2000-06-27 MX MXPA01012726A patent/MXPA01012726A/es active IP Right Grant
- 2000-06-27 DK DK00944671T patent/DK1200073T3/da active
- 2000-06-27 AU AU58732/00A patent/AU773304B2/en not_active Ceased
- 2000-06-27 DE DE60032905T patent/DE60032905T2/de not_active Expired - Lifetime
- 2000-06-27 CN CNB008096880A patent/CN1230174C/zh not_active Expired - Fee Related
- 2000-06-27 US US10/009,655 patent/US6566370B1/en not_active Expired - Fee Related
- 2000-06-27 HU HU0202253A patent/HUP0202253A3/hu unknown
- 2000-06-27 HR HR20020013A patent/HRP20020013A2/hr not_active Application Discontinuation
- 2000-06-27 WO PCT/US2000/016297 patent/WO2001001972A2/en not_active Ceased
- 2000-06-27 NZ NZ515616A patent/NZ515616A/en unknown
- 2000-06-27 CA CA002378613A patent/CA2378613C/en not_active Expired - Fee Related
- 2000-06-27 ES ES00944671T patent/ES2278619T3/es not_active Expired - Lifetime
- 2000-06-27 BR BR0012175-4A patent/BR0012175A/pt not_active Application Discontinuation
- 2000-06-27 TR TR2002/00066T patent/TR200200066T2/tr unknown
- 2000-06-27 EA EA200200132A patent/EA004290B1/ru not_active IP Right Cessation
- 2000-06-27 CZ CZ20014488A patent/CZ20014488A3/cs unknown
- 2000-06-27 SK SK11-2002A patent/SK112002A3/sk not_active Application Discontinuation
- 2000-06-29 AR ARP000103296A patent/AR029373A1/es unknown
- 2000-07-04 PE PE2000000672A patent/PE20010299A1/es not_active Application Discontinuation
- 2000-07-04 MY MYPI20003046 patent/MY133503A/en unknown
2001
- 2001-12-19 NO NO20016246A patent/NO20016246L/no not_active Application Discontinuation
2003
- 2003-03-06 US US10/383,296 patent/US6759418B2/en not_active Expired - Fee Related
2004
- 2004-04-09 US US10/821,698 patent/US6855823B2/en not_active Expired - Fee Related
2005
- 2005-01-11 US US11/032,759 patent/US7157582B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CZ20014488A3 (cs)	2003-01-15
CA2378613C (en)	2007-10-02
US20040192722A1 (en)	2004-09-30
ES2278619T3 (es)	2007-08-16
TR200200066T2 (tr)	2002-04-22
EA004290B1 (ru)	2004-02-26
CA2378613A1 (en)	2001-01-11
PT1200073E (pt)	2007-03-30
HUP0202253A3 (en)	2003-12-29
US20050159445A1 (en)	2005-07-21
US20030199546A1 (en)	2003-10-23
AU5873200A (en)	2001-01-22
BR0012175A (pt)	2002-03-05
DZ3209A1 (fr)	2001-01-11
EP1200073A2 (en)	2002-05-02
US6759418B2 (en)	2004-07-06
PE20010299A1 (es)	2001-03-07
US6566370B1 (en)	2003-05-20
JP2003503449A (ja)	2003-01-28
HRP20020013A2 (en)	2003-08-31
WO2001001972A2 (en)	2001-01-11
EP1200073B1 (en)	2007-01-10
NZ515616A (en)	2004-05-28
IL146697A0 (en)	2002-07-25
JP4619595B2 (ja)	2011-01-26
AR029373A1 (es)	2003-06-25
CN1230174C (zh)	2005-12-07
DE60032905T2 (de)	2007-10-18
WO2001001972A3 (en)	2001-12-06
US7157582B2 (en)	2007-01-02
AU773304B2 (en)	2004-05-20
NO20016246L (no)	2002-03-04
DE60032905D1 (de)	2007-02-22
CN1359289A (zh)	2002-07-17
HUP0202253A2 (hu)	2002-11-28
KR20020024300A (ko)	2002-03-29
US6855823B2 (en)	2005-02-15
HK1047036A1 (zh)	2003-02-07
EA200200132A1 (ru)	2002-06-27
MXPA01012726A (es)	2002-07-02
SK112002A3 (en)	2003-05-02
NO20016246D0 (no)	2001-12-19
MY133503A (en)	2007-11-30

Publication	Publication Date	Title
DK1200073T3 (da)	2007-05-07	Selektive iGluR5-receptorantagonister til behandling af migræne
DK1339678T3 (da)	2008-02-04	Selektive agonister til EP4-receptor til behandling af osteoporose
DK1208095T3 (da)	2004-09-20	Dibenzopyraner som glucocorticoidreceptorantagonister til behandling af diabetes
EE200200355A (et)	2003-10-15	EP4 retseptori selektiivsed agonistid osteoporoosi raviks
DK1144395T3 (da)	2005-08-15	2-amino-benzoxazinon-derivater til behandling af fedme
CY2010003I2 (el)	2012-01-25	Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
DE60026169D1 (de)	2006-04-27	Selektive neurokinin-antagonisten
DK1147083T3 (da)	2004-08-16	Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1221952T3 (da)	2005-08-29	Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler
NO20015779L (no)	2001-11-27	Bradykinin-reseptorantagonister
NO20013997D0 (no)	2001-08-16	Reseptoranalyse
NO20016053D0 (no)	2001-12-11	IL-8 reseptor-antagonister
DK1187833T3 (da)	2007-10-08	Fremgangsmåde til fremstilling af thiamethoxam
NO20016052L (no)	2001-12-11	IL-8-reseptor-antagonister
DK1180028T3 (da)	2007-05-21	IL-8-receptorantagonister
DK1121356T3 (da)	2003-03-24	3-tetrahydropyridin-4-yl-indoler til behandling af psykotiske lidelser
DE60016769D1 (de)	2005-01-20	Antagonisten des vitronectin-receptors
NO20015774D0 (no)	2001-11-27	IL-8 reseptorantagonister
NO20021295L (no)	2002-05-14	Nikotinsyreacetylcholin-reseptor
DK1088817T3 (da)	2003-04-22	Fremgangsmåde til fremstilling af 3-acyl-indoler
IS5897A (is)	2001-03-16	Úreídópíperidín afleiður sem valvís NK3 viðtakamótlyf fyrir manneskjur
DK1451177T3 (da)	2007-07-02	Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne
DK1500396T3 (da)	2005-12-19	Reboxetin til behandling af migrænehovedpiner
NO20022142D0 (no)	2002-05-03	Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
NO20016102L (no)	2002-02-12	IL-8 reseptorantagonister